EUVIMEDEUVIMED entdecken
Open Access

Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, and Colorectal Cancer

Rebecca Boutin, Hiu-Fung Lee, Tian Lai Guan, Tan Trieu Nguyen, Xian Fang Huang, Daniel D Waller, Jordan Lu, Iok In Christine Chio, René P Michel, Michael Sebag, Youla S Tsantrizos iD

Journal of Medicinal Chemistry · 2023

DOI: 10.1021/acs.jmedchem.3c01271 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, 2023. Verfasst von Rebecca Boutin und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Chemistry, McGill University, Montreal, Québec H3A 0B8, Canada. Hauptthemen laut MEDLINE: Multiple Myeloma, Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal, Colorectal Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 89 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Novel C6-substituted pyrazolo[3,4-d]pyrimidine- and C2-substituted purine-based bisphosphonate (C6-PyraP-BP and C2-Pur-BP, respectively) inhibitors of the human geranylgeranyl pyrophosphate synthase (hGGPPS) were designed and evaluated for their ability to block the proliferation of multiple myeloma (MM), pancreatic ductal adenocarcinoma (PDAC), and colorectal cancer (CRC) cells. Pyrazolo[3,4-d]pyrimidine analogs were identified that induce selective intracellular target engagement leading to apoptosis and downregulate the prenylation of Rap-1A in MM, PDAC, and CRC cells. The C6-PyraP-BP inhibitor RB-07-16 was found to exhibit antitumor efficacy in xenograft mouse models of MM and PDAC, significantly reducing tumor growth without substantially increasing liver enzymes or causing significant histopathologic damage, usually associated with hepatotoxicity. RB-07-16 is a metabolically stable compound in cross-species liver microsomes, does not inhibit key CYP 450 enzymes, and exhibits good systemic circulation in rat. Collectively, the current studies provide encouraging support for further optimization of the pyrazolo[3,4-d]pyrimidine-based GGPPS inhibitors as potential human therapeutics for various cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple MyelomaPancreatic NeoplasmsCarcinoma, Pancreatic DuctalColorectal NeoplasmsHumansMiceRatsAnimalsGeranylgeranyl-Diphosphate GeranylgeranyltransferaseDiphosphonatesApoptosisPyrimidinesCell Line, TumorCell ProliferationXenograft Model Antitumor Assays

Substanzen

Geranylgeranyl-Diphosphate GeranylgeranyltransferaseDiphosphonatesPyrimidines

Autor:innen und Institutionen

  • Department of Chemistry, McGill University, Montreal, Québec H3A 0B8, Canada.
  • Department of Biochemistry, McGill University, Montreal, Québec H3G 1Y6, Canada.
  • Department of Medicine, McGill University, Montreal, Québec H3A 1A1, Canada.
  • Terry Fox Laboratory, BC Cancer Research Institute, Vancouver, British Columbia V5Z 1L3, Canada.
  • Institute for Cancer Genetics, Department of Genetics and Development, Columbia University Irving Medical Center, New York, New York 10032, United States.
  • Herbert Irving Comprehensive Cancer Center, Columbia University Irving Medical Center, New York, New York 10032, United States.

ORCID-Profile: Youla S Tsantrizos

Förderung

  • NCI NIH HHS
  • Canadian Institutes of Health Research

Zitieren

APA

Boutin, R., Lee, H. F., Guan, T. L., Nguyen, T. T., Huang, X. F., Waller, D. D., Lu, J., Christine Chio, I. I., Michel, R. P., Sebag, M., & Tsantrizos, Y. S. (2023). Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, and Colorectal Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.3c01271

Vancouver

Boutin R, Lee HF, Guan TL, Nguyen TT, Huang XF, Waller DD, et al. Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, and Colorectal Cancer. Journal of Medicinal Chemistry. 2023. doi:10.1021/acs.jmedchem.3c01271

BibTeX
@article{Boutin2023,
  author = {Boutin, Rebecca and Lee, Hiu-Fung and Guan, Tian Lai and Nguyen, Tan Trieu and Huang, Xian Fang and Waller, Daniel D and Lu, Jordan and Christine Chio, Iok In and Michel, René P and Sebag, Michael and Tsantrizos, Youla S},
  title = {Discovery and Evaluation of C6-Substituted Pyrazolopyrimidine-Based Bisphosphonate Inhibitors of the Human Geranylgeranyl Pyrophosphate Synthase and Evaluation of Their Antitumor Efficacy in Multiple Myeloma, Pancreatic Ductal Adenocarcinoma, and Colorectal Cancer},
  journal = {Journal of Medicinal Chemistry},
  year = {2023},
  doi = {10.1021/acs.jmedchem.3c01271}
}
Kostenlos starten →